Agreement with Bayer Schering Pharma


Our attorneys represented Novartis in an agreement with Bayer Schering Pharma AG that will provide Novartis the opportunity to introduce its own branded version of interferon beta-1b for patients with the debilitating neurological disease multiple sclerosis (MS). Bayer Schering Pharma will provide regulatory support and supply this medicine to Novartis in return for royalty payments. In addition, Novartis will transfer manufacturing responsibility for interferon beta-1b to Bayer Schering Pharma, which will purchase the related equipment and inventory as well as lease certain buildings at a Novartis site in Emeryville, California.

Email Disclaimer